ZymoGenetics (NASDAQ: [[ticker:ZGEN]]), the Seattle-based developer of a treatment to stop excess surgical bleeding, said today that its partner has voluntarily withdrawn an application to market the product in Europe. Germany-based Bayer, who formed a collaboration with ZymoGenetics to market recombinant thrombin (Recothrom) in 2007, withdrew the European application after regulators there said another clinical trial would be necessary to win approval, according to a regulatory filing. The drug won FDA clearance in January 2008. The product has gotten off to a slow start in the U.S., where it is estimated to generate $28 million to $30 million in sales this year.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
